Verona Pharma (VRNA) reported a Q3 loss Monday of $0.07 per diluted share, wider than the loss of $0.02 a year earlier.
Analysts surveyed by Capital IQ expected a loss of $0.32 per share.
Revenue for the quarter ended Sept. 30 was $5.6 million. The company did not report any revenue a year earlier.
Analysts polled by Capital IQ expected $1.5 million.
As of Sept. 30, the company had $336 million in cash and cash equivalents, with an expected cash runway of until at least the end of 2026.
Price: 34.96, Change: -0.02, Percent Change: -0.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments